This is a translation of the original article in Portuguese. Read the original (Português).
A blood test marketed as capable of detecting more than 50 types of cancer failed to identify the disease in 69% of cases in which it was present. The information comes from a report by the Brazilian news portal G1.
In practice, this means that, out of every ten people with cancer who are tested, about seven would receive a negative result even though they are sick. Doctors call this a false negative.
The figure helps clarify the difference between two concepts used to evaluate tests. Sensitivity measures a test’s ability to identify people who have the disease: the lower it is, the more cases go unnoticed. Specificity measures a test’s ability to clear people who do not have the disease: the lower it is, the more false alarms. The number published by G1 refers to the first, the one concerning missed cases.
Why this matters: multi-cancer screening tests are often offered to people without symptoms, especially those between 40 and 60 years old. For this group, a negative result can create a false sense of security and lead people to postpone medical appointments or skip tests that are already recommended, thereby delaying a diagnosis.
For anyone considering the test, the result is a warning: a negative test does not guarantee the absence of cancer. The test therefore does not replace the screening tests already recommended, such as those for breast, cervical and colorectal cancer, nor does it replace attention to symptoms and regular medical follow-up.
The test is presented as a way to expand early detection with a single blood draw, which makes it appealing. G1’s report shows, however, that the promise of broad coverage is not accompanied, in this analysis, by performance that would allow people to trust a negative result.
Anyone with a family history of cancer, persistent symptoms or doubts about which tests to take should talk to a doctor before deciding on this test.
Reporting from G1 (Reportagem nacional: exame de sangue para câncer falha em 69% dos casos).
Deixe um comentário